Log In
BCIQ
Print this Print this
 

SelK2

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionHumanized mAb against P selectin glycoprotein ligand-1 (PSGL-1)
Molecular Target P selectin glycoprotein ligand-1 (PSGL-1) (CD162) (SELPLG)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationCrohn's disease
Indication DetailsTreat Crohn's disease
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$665.0M

$10.0M

$415.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/21/2016

$665.0M

$10.0M

$415.0M

Get a free BioCentury trial today